Cord tissue-derived MSCs (Mesenchymal Stem Cells), have been shown to improve post-acute COVID-19 symptoms by significantly decreasing inflammatory cytokines, modulating the immune system, and improving recovery times.
Can stem cells help COVID-19 Patients?
Since the COVID-19 pandemic began there have been many studies conducted that aim to determine the safety and explore the efficacy of umbilical cord mesenchymal stem cell (UC‐MSC) infusions in subjects with COVID‐19. Mesenchymal stem cells administered intravenously may be able to significantly reduce significant adverse reactions, mortality, and time to recovery, in COVID-19 patients.
Stem cell treatment goals for post-acute COVID-19 syndrome
The therapeutic uses of stem cells as a potential therapy for a variety of diseases has been immensely explored, the number of clinical trials conducted with Mesenchymal Stem Cells has increased exponentially over the past few years.
What is post-acute COVID-19 Syndrome?
Similar to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms.
The stated primary goal of our COVID-19 protocol is the marked reduction in the levels of chronic low-grade inflammation for an extended period.
Stem cells have a unique, intrinsic property that attracts them to inflammation in the body. Studies have shown that stem cells can regenerate damaged or diseased tissues, reduce inflammation and modulate the immune system promoting better health and quality of life.
In regards to post-acute COVID-19 syndrome, patients can expect fewer long-term complications, improved recovery time, a reduction in persistent COVID-19 related symptoms & an overall decrease in inflammation throughout the body.
Critically ill COVID-19 Patient Successfully Treated with Mesenchymal Stem Cells
DVC Stem’s partner lab Vitro Biopharma received emergency use authorization from the FDA to treat a critically ill COVID-19 patient with mesenchymal stem cells in the United States.
